Archive:
In addition to other topics relevant to the pharmaceutical market, the law for greater security in the supply of pharmaceuticals (GSAV) in 2019 also stipulated regulations that affect the biosimilar market in the GKV. With the GSAV, certain new regulations have already been created and implemented, but additional changes are also promised after a period of three years. The latter relate not least to the planned interchangeability of biosimilars in pharmacies from 2022. Against this background, the authors of this article have published a scientific report, which is available as a full publication online under the “eFirst” section of the “Monitor Healthcare Research” (https: //www.monitor-sorgesforschung.de/efirst/Versorgung_Bios_2022/view), considerations were given as to which regulatory framework would do justice to the special market situation of biosimilars, particularly with regard to pricing (Bauer et al. 2021). The model developed in this context, which is intended as an alternative or counter-proposal to (partial/exclusive) discount contract tenders - which will be the logical consequence of the GSAV regulations - is presented below. This reimbursement and pricing model is intended to do justice to the market conditions analyzed in detail in the full publication in the sense of a sustainable competition concept in the biosimilar market and to be introduced into the health policy discussion.
01.02.2021
Thesis paper 7.0 builds on the previous papers published in “Monitor Healthcare Research” (from MVF 03/20), updates the epidemiological analysis and focuses on vaccination and the classification of vaccination in the current epidemiological situation and the prevention concept . According to the authors, organizing a vaccination campaign is one of the most demanding tasks for a society and must be planned (and evaluated) like a multiple intervention, and individual information about vaccination is also mandatory. Three goals and strategies for the vaccination campaign are also conceivable, which are set out in the full text paper. The article published here is a short version of the full version, which has already been published in an online first version by MVF. Was standing; January 10, 2021, 12:00 p.m
01.02.2021
Since 2008, the Federal Ministry of Education and Research (BMBF) alone has invested significantly more than 100 million euros in research and development projects for age-appropriate assistance technology1. These include, for example, computer games to maintain mental fitness and performance, especially of older and very old people, or telemonitoring and telecare systems to support medical care, especially in rural areas. Care robots such as the seal Paro and household or service robots are also mentioned, which are intended to enable people with physical and psychological disabilities to live a self-determined life within their own four walls (Weber 2017). Other ministries are also funding similar projects on a large scale at federal and state level, as is the European Union. This funding is justified by two social developments, both of which are continually being discussed publicly.
01.02.2021
The aim of this study was to shed light on the care situations of patients with initial SCS therapy and to look at the effects on pain diagnoses and comorbidities as well as cost structures in a period from one year before to three years after the start of therapy. Due to the variety of international literature on the cost effectiveness of different types of devices, the further question was whether a difference could also be recognized in the German context.
01.02.2021
Over 500 0nline participants followed the first digital BMC congress, which has been the first major meeting of the year for the healthcare industry in a long time, where people meet, exchange ideas, network and get to know each other. This time everything is different due to Corona, what remains the same is the quality of the lectures and sessions. After the welcome from Prof. Dr. Volker Amelung, chairman of the BMC, gave the opening speech in the first part of the congress, which was simply titled “digital”, and was given by Federal Health Minister Jens Spahn. This was followed by a keynote speech by Prof. Dr. Ellen Nolte (London School of Hygiene & Tropical Medicine), Klaus Bürg (Amazon Web Services) and Katharina Jünger (Teleclinic). It was moderated by the outgoing BMC managing director Dr. Patricia Ex.
01.02.2021
With this part of the series “Health care research made in” “Monitor Health Care Research” presents an institute from a German-speaking neighboring country for the first time. When healthcare researchers in this country complain that public health funding from the end of the 1980s was not sustainable enough and also want to see the billions of euros from the Innovation Fund's budget pot distributed better, and in any case differently, the Austrian researchers can only be amazed Shake your head: With them there was and is neither. It is all the more surprising that there is still a lively health care research scene in Austria. For example, the Institute for General Medicine and Evidence-Based Health Care Research (IAMEV) at the Medical University of Graz, which has been headed since its founding by Professor Dr. med.univ. Andrea Siebenhofer-Kroitzsch.
01.02.2021
Fast 15.000 Studierende haben sich deutschlandweit an einer Onlinebefragung zur digitalen Gesundheitskompetenz in Zeiten von Corona beteiligt. Forschende der Universität Bielefeld und der Hochschule Fulda fragten nach der Informati-onssuche und -zufriedenheit, dem Umgang mit digitalen Informationen sowie der psychischen Gesundheit während der Pandemie. Der Großteil der Studierenden verfügt der Studie zufolge über eine ausreichende digitale Gesundheitskompetenz. Doch mehr als 42 Prozent der Befragten berichten von Schwierigkeiten, die Qualität der Gesundheitsinformationen zum Coronavirus zu bewerten.
01.02.2021
10 years of AMNOG (Medicines Market Reorganization Act) is an occasion for many individual and institutional status reports. In a UCEF workshop in Rostock (Independent Center for Market and Social Research), representatives from the areas of health policy, market access and reimbursement brought together their experiences on product evaluations.
01.02.2021
The Janssen Open House, which took place digitally for the first time this year, once again offered a 360-degree perspective on medically relevant topics of the present and future. The participants of the #JOH2020 received innovative and visionary impulses, but also experienced an intensive exchange - despite the purely virtual format. Among those present was Dr. Paul Stoffels, global head of research at Johnson & Johnson, who presented Janssen's research activities, including in relation to Covid-19.
01.02.2021
Die medikamentöse Behandlung der Rheumatoiden Arthritis wurde in den letzten beiden Jahrzehnten um zwei neue Arzneimittelgruppen erweitert und bietet den Ärzten zusätzliche Therapieoptionen. Doch welche Empfehlungen zur Pharmakotherapie gibt es, wie sieht die Arzneimitteltherapie in der Praxis aus und wohin entwickelt sich diese möglicherweise weiter? Diese Fragen werden im folgenden Beitrag durch die Darstellung einzelner Aspekte in Ansätzen beleuchtet.